



## Novel Vaccines for Infectious Pathogens

Guest Editors:

### **Dr. Veerupaxagouda Patil**

Center for Food Animal Health,  
Department of Animal Sciences,  
College of Food, Agricultural, and  
Environmental Sciences (CFAES),  
Ohio Agricultural Research and  
Development Center, Wooster,  
OH 44691, USA

### **Dr. Dhruv Desai**

Ryan Veterinary Hospital, School  
of Veterinary Medicine, University  
of Pennsylvania, 3900 Spruce St,  
Philadelphia, PA 19104, USA

Deadline for manuscript  
submissions:

**31 March 2025**

### **Message from the Guest Editors**

Vaccines are one of the most important life-saving public health tools. In this Special Issue, original research articles and literature or perspective reviews are welcome. Research areas may include, but are not limited to, the following: novel vaccines based on a variety of platforms/delivery/mechanism of action (innate immunity-based, trained immunity-based, CRISPR-based, AI-based, immunoinformatics-based, multi-omics-based, nanotechnology-based, mucosal nanovaccines, nucleic acid-based, protein subunit-based, cytotoxic T-cell-based, peptide epitope-based vaccines, nanoemulsion-based, plant-based, dendritic cell-based, vector-based, mRNA-based) against zoonotic and emerging infectious diseases of food for animals and humans, caused by viruses, such as swine influenza A viruses, avian influenza A viruses, and multi drug-resistant zoonotic pathogens, such as methicillin-resistant *Staphylococcus aureus* (MRSA), *Pseudomonas aeruginosa*, and carbapenem-resistant enterobacterales (CRE), all of which are welcome.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)